Supernus Pharmaceuticals (SUPN) Current Assets (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Current Assets of $723.5 million for Q2 2026, down 2.08% year-over-year from $738.9 million in Q2 2025, and down 1.11% on a QoQ basis from $731.6 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Current Assets (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Current Assets for 16 years, with the latest figure at $723.5 million in Q2 2026.
- Current Assets for Q2 2026 came in at $723.5 million, down 2.08% year-over-year; the trailing twelve-month figure through Jun 2026 was $723.5 million (down 2.08% YoY), and the FY2025 annual result was $644.2 million, down 6.11% from the prior year.
- Current Assets declined to $723.5 million in Q2 2026, from $731.6 million in the prior quarter.
- Over five years, Current Assets peaked at $883.3 million in Q1 2023 and troughed at $423.5 million in Q2 2023.
- A 5-year average of $634.6 million and a median of $642.1 million in 2024 frame the typical range for Current Assets.
- The widest annual swing landed in 2023, when Current Assets soared 55.38%; it then plunged 38.38% in 2024.
- A 5-year view of Current Assets shows it stood at $734.2 million in 2022, then plunged by 32.83% to $493.1 million in 2023, then jumped by 39.13% to $686.1 million in 2024, then declined by 6.11% to $644.2 million in 2025, then increased by 12.31% to $723.5 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $723.5 million in Q2 2026, $731.6 million in Q1 2026, and $644.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 3.22 Bn |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 723.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 723.50 Mn |
| Mar 31, 2026 | 731.58 Mn |
| Dec 31, 2025 | 644.18 Mn |
| Sep 30, 2025 | 593.89 Mn |
| Jun 30, 2025 | 738.87 Mn |
| Mar 31, 2025 | 687.58 Mn |
| Dec 31, 2024 | 686.07 Mn |
| Sep 30, 2024 | 640.00 Mn |
| Jun 30, 2024 | 591.00 Mn |
| Mar 31, 2024 | 544.32 Mn |
| Dec 31, 2023 | 493.11 Mn |
| Sep 30, 2023 | 449.36 Mn |
| Jun 30, 2023 | 423.54 Mn |
| Mar 31, 2023 | 883.34 Mn |
| Dec 31, 2022 | 734.15 Mn |
| Sep 30, 2022 | 663.89 Mn |
| Jun 30, 2022 | 625.12 Mn |
| Mar 31, 2022 | 568.52 Mn |
| Dec 31, 2021 | 601.59 Mn |
| Sep 30, 2021 | 668.38 Mn |